Naoyuki G. Saito
Physics and Astronomy · Indiana University
Publications
61
Citations
1,545
Est. group size
—
Recurring co-author estimate
Active years
48
Publishing since 1978
Naoyuki G. Saito conducts research in clinical oncology, focusing on cancer treatment using radiation therapy and, increasingly, machine learning and deep learning methods to predict which patients will benefit from specific therapies. This work spans multiple cancer types, including colon, prostate, liver, and lymphoma, and often draws on data from large randomized clinical trials. Studies also examine the tumor immune environment to guide treatment decisions.
Publication activity has been steady over the last decade, averaging roughly two papers per year.
Generated by claude-opus-4-8 from public bibliographic data · Jul 9, 2026
Typically publishes in teams of ~17 · 7% small-team papers (≤3 authors) · across 7 venues
- NCCN Guidelines® Insights: B-Cell Lymphomas 3.2025
Journal of the National Comprehensive Cancer Network · 2025
- Erratum: Machine Learning Predicts Oxaliplatin Benefit in Early Colon Cancer
Journal of Clinical Oncology · 2025
- Machine Learning Predicts Oxaliplatin Benefit in Early Colon Cancer
Journal of Clinical Oncology · 2024
- Author Correction: Prostate cancer therapy personalization via multi-modal deep learning on randomized phase III clinical trials
npj Digital Medicine · 2023
- Prostate cancer therapy personalization via multi-modal deep learning on randomized phase III clinical trials
npj Digital Medicine · 2022
- Testing of a machine learning (ML) model for ability to predict oxaliplatin and bevacizumab (bev) benefit in NRG Oncology/NSABP C-07 and C-08.
Journal of Clinical Oncology · 2022
- Association of multiplex-immunofluorescence (m-IF) and gene expression signature with prognosis and bevacizumab (bev) treatment outcomes in NRG oncology/NSABP C-08: Implications for combining immune checkpoint blockade (ICB) and bev.
Journal of Clinical Oncology · 2022
- Examination of the tumor immune microenvironment (TIME) with multispectral immunofluorescence (m-IF): Association of markers with prognosis and bevacizumab (bev) benefit in NRG Oncology/NSABP C-08.
Journal of Clinical Oncology · 2021
- MSOR09 Presentation Time: 10:40 AM
Brachytherapy · 2021
- A Retrospective Analysis of 287 Patients Undergoing Prophylactic Radiation Therapy for the Prevention of Heterotopic Ossification
Advances in Radiation Oncology · 2020
- An Intracranial Hemorrhage Wrapped in an Enigma
International Journal of Radiation Oncology*Biology*Physics · 2019
- A Retrospective Analysis of 287 Patients Undergoing Prophylactic Radiation Therapy for the Prevention of Heterotopic Ossification
International Journal of Radiation Oncology*Biology*Physics · 2019
- Congenital ichthyosis patient with squamous cell carcinoma of the skin who received concurrent chemoradiation: A case report
Advances in Radiation Oncology · 2017
- Congenital ichthyosis patient with squamous cell carcinoma of the skin who received concurrent chemoradiation: A case report
PMC · 2017
- Stereotactic body radiation therapy to generate comparable survival to surgery in treating hepatocellular carcinoma (HCC): Results of 756 patients.
Journal of Clinical Oncology · 2017
- Journal of Clinical Oncology×6
- International Journal of Radiation Oncology*Biology*Physics×3
- npj Digital Medicine×2
- Advances in Radiation Oncology×2
- Journal of the National Comprehensive Cancer Network×1
- Dale W. Litzenberg
Physics and Astronomy · University of Michigan
- J Woollard
Physics and Astronomy · The Ohio State University
- Charles S. Mayo
Physics and Astronomy · University of Michigan
- D Litzenberg
Physics and Astronomy · University of Michigan
- Jean M. Moran
Physics and Astronomy · University of Michigan
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 27, 2026.
Claim or correct this profile